Leonid Beigelman
Geen lopende functies
Vermogen: 1 M $ op 31-03-2024
Loopbaan van Leonid Beigelman
Eerdere bekende functies van Leonid Beigelman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALIGOS THERAPEUTICS, INC. | Director/Board Member | 01-02-2018 | 09-11-2023 |
President | 01-02-2018 | 01-12-2023 | |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01-09-2014 | 01-03-2018 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 20-12-2012 | 01-11-2014 |
Founder | 01-01-2008 | 01-11-2014 | |
INTERMUNE INC | Corporate Officer/Principal | 01-01-2005 | 01-01-2009 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Corporate Officer/Principal | 01-01-2002 | 01-01-2005 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-01-1992 | 01-01-2002 |
United States Biochemical Corp.
United States Biochemical Corp. Pharmaceuticals: OtherHealth Technology Part of Ampco-Pittsburgh Corp., United States Biochemical Corp. is an American company that specializes in the production of medicinal and botanical drugs. United States Biochemical was acquired by GE Healthcare Ltd. (United Kingdom) from Ampco-Pittsburgh Corp. on April 06, 1993 for $8.80 million. | Corporate Officer/Principal | 01-01-1991 | - |
Opleiding van Leonid Beigelman
Institute of Molecular Biology | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Operationeel
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 7 |
Commercial Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
ALIGOS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
United States Biochemical Corp.
United States Biochemical Corp. Pharmaceuticals: OtherHealth Technology Part of Ampco-Pittsburgh Corp., United States Biochemical Corp. is an American company that specializes in the production of medicinal and botanical drugs. United States Biochemical was acquired by GE Healthcare Ltd. (United Kingdom) from Ampco-Pittsburgh Corp. on April 06, 1993 for $8.80 million. | Health Technology |
- Beurs
- Insiders
- Leonid Beigelman
- Ervaring